Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney

American Journal of Physiology - Cell Physiology

Volumn 306, Issue 3, 2014, Pages

  Mariappan, Meenalakshmi M ^a,b   De Silva, Kristin ^a   Sorice, Gian Pio ^a   Muscogiuri, Giovanna ^a   Jimenez, Fabio ^a,b   Ahuja, Seema ^a,b   Barnes, Jefferey L ^a,b   Choudhury, Goutam Ghosh ^a,b   Musi, Nicolas ^a,b   de Fronzo, Ralph ^a,b   Kasinath, Balakuntalam S ^a,b  

^a University of Texas Health Science Center   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Hyperglycemia; Hyperinsulinemia; Laminin; MTOR; Renal fibrosis; TGF

Indexed keywords

CHLORDANE; FIBRONECTIN; GLUCOSE; INSULIN; ISOPROSTANE DERIVATIVE; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX PROTEIN; PROTEIN KINASE B; SMAD3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY MASS; MALE; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RNA TRANSLATION; URINARY EXCRETION;

HYPERGLYCEMIA; HYPERINSULINEMIA; LAMININ; MTOR; RENAL FIBROSIS; TGF-Β;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME ACTIVATION; FIBRONECTINS; FIBROSIS; HYPERGLYCEMIA; HYPERINSULINISM; INFLAMMATION; KIDNEY; LAMININ; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SMAD3 PROTEIN; TOLL-LIKE RECEPTOR 4; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893364356     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00144.2013     Document Type: Article

References (52)

1. Bell DS, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 14: 112-124, 2008.
2. Bhandari BK, Feliers D, Duraisamy S, Stewart JL, Gingras AC, Abboud HE, Choudhury GG, Sonenberg N, Kasinath BS. Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int 59: 866-875, 2001.
3. Böttinger EP. TGF-beta in renal injury and disease. Semin Nephrol 27: 309-320, 2007.
4. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295: 1707-1708, 2006.
5. Ceriello A. Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? Diabetes Care 32: 521-522, 2009.
6. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 21: 171-175, 2004.
7. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res 57: 199-204, 2008.
8. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care 34: 177-180, 2011.
9. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280: 25485-25490, 2005.
10. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 124 years. Diabetes Care 22: 233-240, 1999.
11. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, Riley DJ, Kasinath BS, Choudhury GG. Raptor-rictor axis in TGFbeta-induced protein synthesis. Cell Signal 20: 409-423, 2008.
12. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53: 1270-1287, 2010.
13. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1-and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471, 2006.
14. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205: 2409-2417, 2008.
15. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30: 49-59, 2012.
16. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072, 2002.
17. Feliers D, Gorin Y, Ghosh-Choudhury G, Abboud HE, Kasinath BS. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am J Physiol Renal Physiol 290: F927-F936, 2006.
18. Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 44: 290-303, 2011.
19. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 19: 583-592, 1998.
20. Han, SH, Susztak K. The hyperglycemic and hyperinsulinemic combo gives you diabetic kidney disease immediately. Focus on "Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. " Am J Physiol Cell Physiol (December 11, 2013). doi: 10. 1152/ajpcell. 00371. 2013.
21. Hill C, Flyvbjerg A, Gronbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141: 1196-1208, 2000.
22. Hutchinson JA, Shanware NP, Chang H, Tibbetts RS. Regulation of ribosomal protein S6 phosphorylation by casein kinase 1 and protein phosphatase 1. J Biol Chem 286: 8688-8696, 2011.
23. Kasinath BS, Feliers D, Sataranatarajan K, Ghosh Choudhury G, Lee MJ, Mariappan MM. Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 297: F1153-F1165, 2009.
24. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Ghosh Choudhury G, Feliers D. Novel mechanisms of protein synthesis in diabetic nephropathy-role of mRNA translation. Rev Endocr Metab Disord 9: 255-266, 2008.
25. Kazi AA, Hong-Brown L, Lang SM, Lang CH. Deptor knockdown enhances mTOR activity and protein synthesis in myocytes and ameliorates disuse muscle atrophy. Mol Med 17: 925-236, 2011.
26. Lautt WW. Postprandial insulin resistance as an early predictor of cardiovascular risk. Ther Clin Risk Manag 3: 761-770, 2007.
27. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47: 443-467, 2007.
28. Lee HJ, Mariappan MM, Feliers D, Cavaglieri RC, Sataranatarajan K, Abboud HE, Choudhury GG, Kasinath BS. Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating AMPactivated protein kinase in renal epithelial cells. J Biol Chem 287: 4451-4461, 2012.
29. Lee M, Feliers D, Mariappan MM, Natarajan K, Mahimainathan L, Musi N, Ghosh Choudhury G, Kasinath BS. AMP kinase (AMPK)-a new regulator of renal hypertrophy in diabetes (Abstract). J Am Soc Nephrol 16: 196A, 2005.
30. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS. A role for AMP-activated protein kinase in diabetesinduced renal hypertrophy. Am J Physiol Renal Physiol 292: F617-F627, 2007.
31. Luzi L, Petrides AS, De Fronzo RA. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM. Diabetes 42: 1868-1877, 1993.
32. Maeda S. Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? Kidney Int 74: 413-415, 2008.
33. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, Kasinath BS. High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 56: 476-485, 2007.
34. McGowan TA, Dunn SR, Falkner B, Sharma K. Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans. Clin J Am Soc Nephrol 1: 263-268, 2006.
35. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512, 2004.
36. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681-1687, 2006.
37. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 8: 23, 2009.
38. Park IS, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor-beta and type IV collagen in early streptozotocininduced diabetes. Diabetes 46: 473-480, 1997.
39. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, Sonenberg N. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 12: 235-245, 2011.
40. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
41. Polhill TS, Saad S, Poronnik P, Fulcher GR, Pollock CA. Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am J Physiol Renal Physiol 287: F268-F273, 2004.
42. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510-1515, 1987.
43. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 11: e13, 2009.
44. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791, 2006.
45. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002.
46. Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies. J Med Chem 47: 4113-4117, 2004.
47. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731-745, 2009.
48. Stegenga ME, van der Crabben SN, Dessing MC, Pater JM, van den Pangaart PS, de Vos AF, Tanck MW, Roos D, Sauerwein HP, van der Poll T. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 25: 157-164, 2008.
49. Takahashi F, Hasebe N, Kawashima E, Takehara N, Aizawa Y, Akasaka K, Kawamura Y, Kikuchi K. Hyperinsulinemia is an independent predictor for complex atherosclerotic lesion of thoracic aorta in non-diabetic patients. Atherosclerosis 187: 336-342, 2006.
50. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140: 805-820, 2010.
51. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794, 1999.
52. Winhofer Y, Krssak M, Jankovic D, Anderwald CH, Reiter G, Hofer A, Trattnig S, Luger A, Krebs M. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes 61: 1210-1216, 2012.